EU pharmaceutical regulation reforms needed to drive innovation and investment, experts suggest

New research from Bayes Business School, in collaboration with biopharmaceuticals company Merck KGaA, suggests member states from the European Union (EU) must work more closely together, provide better incentives for the development of new medicines and approve access to medicines quicker than other international regulators, if it is to attract greater investment from pharmaceutical companies.

👉 Full Story